1. Scrip
  2. >>Business
  3. >>Deals

How Will Pharma M&A Change In 2017?

 
• By Lucie Ellis-Taitt
  
Generate a summary of this article
Listen to this article
Beta

Industry consultants survey the landscape for pharma deal making in 2017. More deals, higher prices and asset swaps as repatriated cash burns holes in US pharma's pockets are just for starters.

Curtain of darkness
How will the pharma M&A landscape change in 2017? • Source: Shutterstock

In October 2016, US companies unleashed an unprecedented wave of deals, making it the busiest month ever for domestic M&A, despite what had been a lackluster start to the year. This momentum for M&A is expected to continue into 2017 and, according to a recent report from Deloitte, which surveyed 1,000 executives to gauge their expectations for M&A activity, the magnitude of individual transactions this year will exceed the size of deals seen in 2016.

In the report titled M&A Trends: Year-end Report 2016, Deloitte found that 75% of respondents expected deal activity...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.